Astronaut Sight Loss 🚀: Fixing Space Vision 👁️

THE GROWING CONCERN OF SPACE-RELATED VISION LOSS
The European Space Agency (ESA) is proactively investigating the phenomenon of astronauts losing their eyesight during space missions, driven by the increasing risk posed by longer-duration spaceflights. This research is crucial to developing potential treatments or preventative measures for Spaceflight-Associated Neuro-ocular Syndrome (SANS).

SILOTON: A QUANTUM SOLUTION
British eye-scanning startup Siloton has been commissioned by the ESA to develop a solution to address this critical issue. Siloton utilizes quantum technology to miniaturize traditional eye-testing equipment, creating a photonic chip smaller than a coin. The company’s work with the UK’s National Health Service (NHS) demonstrates this technology’s potential for at-home retinal scanning, a model the ESA is adapting for space applications.

SPACEFLIGHT-ASSOCIATED NEURO-OCULAR SYNDROME (SANS)
Spaceflight-Associated Neuro-ocular Syndrome (SANS) represents a significant health risk for astronauts, characterized by a range of eye and brain changes caused by prolonged exposure to low-gravity environments. Approximately 70% of astronauts on the International Space Station (ISS) experience SANS. The condition is linked to fluid accumulation in the head, leading to eyeball compression, optic nerve swelling, and retinal displacement.

THE JOHN PHILLIPS CASE: A STARK ILLUSTRATION
The case of NASA astronaut John Phillips, who launched in 2005 with 20/20 vision and splashed down six months later with a visual impairment of 20/100, provides a stark example of SANS’s impact. During his mission, the effects of microgravity caused significant fluid buildup, directly impacting his vision. This highlights the operational risks and long-term health concerns associated with the condition.

RETINAL MONITORING AND THE CHALLENGES OF REMOTE GUIDANCE
Scientists are currently monitoring the effects of spaceflight on the human eye using a modified optometry device on the ISS, which measures retinal thickness. However, the device’s bulk and requirement for real-time remote guidance from ground experts present significant challenges, particularly given increasing communication delays with Earth as missions extend into deep space.

SILOTON’S AUTOMATED SCANNING DEVICE
Siloton’s device aims to overcome these limitations by automating the scanning process, eliminating the need for ground support. This will enable astronauts to perform frequent retinal examinations, generating valuable data on ocular degeneration and potentially providing early warning signs of changes before vision loss occurs.

TECHNICAL CONSIDERATIONS AND DESIGN CHALLENGES
Several technical hurdles must be addressed, including powering the device with batteries due to fire risks in spacecraft, accommodating the equipment’s binocular size, and ensuring astronaut head positioning in the absence of gravity. The company’s experience working with elderly patients with pre-existing visual impairments offers a crucial advantage in adapting the technology for astronauts.

COLLABORATION AND TECHNOLOGY TRANSFER
The research and development efforts undertaken for space applications are expected to benefit Siloton’s products for the NHS, and vice versa. This collaborative approach ensures continuous innovation and improvement in both space-based and terrestrial eye-scanning technology, ultimately enhancing patient care.

EARLY DETECTION AND PREVENTATIVE MEASURES
The ESA’s focus on proactive monitoring and early detection of SANS is critical. By gathering comprehensive data on ocular degeneration through Siloton’s automated scanning device, they hope to identify factors contributing to the condition and potentially develop treatments or preventative strategies before vision loss occurs, safeguarding the health and mission capabilities of astronauts.